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Mutations in the Gene Encoding Peroxisomal Sterol Carrier Protein X
(SCPx) Cause Leukencephalopathy with Dystonia and Motor Neuropathy
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In this report, we describe the ﬁrst known patient with a deﬁciency of sterol carrier protein X (SCPx), a peroxisomal
enzyme with thiolase activity, which is required for the breakdown of branched-chain fatty acids. The patient
presented with torticollis and dystonic head tremor as well as slight cerebellar signs with intention tremor, nystagmus,
hyposmia, and azoospermia. Magnetic resonance imaging showed leukencephalopathy and involvement of the
thalamus and pons. Metabolite analyses of plasma revealed an accumulation of the branched-chain fatty acid
pristanic acid, and abnormal bile alcohol glucuronides were excreted in urine. In cultured skin ﬁbroblasts, the
thiolytic activity of SCPx was deﬁcient, and no SCPx protein could be detected by western blotting. Mutation
analysis revealed a homozygous 1-nucleotide insertion, 545_546insA, leading to a frameshift and premature stop
codon (I184fsX7).
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To date, several peroxisomal fatty-acid oxidation defects
due to deﬁciency of a single enzyme and/or protein in
the peroxisome have been identiﬁed, including X-linked
adrenoleukodystrophy (MIM 300100), Refsum dis-
ease (MIM 266500), and a-methylacyl-CoA racemase
(AMACR) deﬁciency (MIM 604489). Peroxisomes play
an important role in the breakdown of very-long-chain
fatty acids (VLCFAs), polyunsaturated fatty acids, and
branched-chain fatty acids, like phytanic and pristanic
acid, but also have a role in the formation of primary
C24-bile acids by b-oxidation of the bile-acid interme-
diates di- and trihydroxycholestanoic acids (DHCA and
THCA).1 Peroxisomes in mammals contain two sets of
b-oxidation enzymes, which differ in substrate speciﬁc-
ity1 (ﬁg. 1). Straight-chain acyl-CoA oxidase (SCOX) is
responsible for the initial oxidation of VLCFAs, whereas
branched-chain acyl-CoA oxidase (BCOX) oxidizes the
branched-chain acyl-CoAs pristanoyl-CoA, DHC-CoA,
and THC-CoA. The enoyl-CoA esters of both straight-
and branched-chain fatty acids are then hydrated and
subsequently dehydrogenated by the same enzyme: D-
bifunctional protein (DBP). The second multifunctional
protein in the peroxisome, L-bifunctional protein, is in-
volved in the degradation of long-chain dicarboxylic ac-
ids, but these acids are also handled by DBP.2 The last
step of the b-oxidation process, thiolytic cleavage, is per-
formed by sterol carrier protein X (SCPx) in the case of
branched-chain substrates, whereas straight-chain sub-
strates are most likely handled by both SCPx and the
classic 3-ketoacyl-CoA thiolase.1 In addition to the b-
oxidation enzymes, AMACR is required for b-oxidation
of branched-chain substrates. Since the peroxisomal b-
oxidation system is stereospeciﬁc and only accepts S iso-
mers as substrate—and pristanic acid naturally occurs
as a mixture of two different diastereomers—(2R)-pris-
tanic acid must ﬁrst be converted to its S isomer before
it can be degraded via b-oxidation (ﬁg. 1). AMACR is
responsible for this conversion and also converts (25R)-
DHCA and (25R)-THCA, formed exclusively from cho-
lesterol, into their respective S isomers. Consequently,
patients with a deﬁciency of AMACR accumulate pris-
tanic acid, DHCA, and THCA.
In addition to patients with an isolated deﬁciency of
SCOX (MIM 264470) or DBP (MIM 261515),1 a pa-
tient with a tentative peroxisomal 3-ketoacyl-CoA thio-
lase deﬁciency has been described, but reinvestigation of
this patient revealed the true defect to be at the level
of DBP.3 All patients with a peroxisomal fatty-acid ox-
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Figure 1 Schematic representation of the fatty-acid b-oxidation machinery in human peroxisomes catalyzing the oxidation of VLCFA-
CoAs and branched-chain fatty acyl-CoAs (pristanoyl-CoA and THC-CoA). Because BCOX can handle only S isomers, (2R)-pristanoyl-CoA
and (25R)-THC-CoA ﬁrst have to be converted to their S isomers by AMACR. Subsequently, the branched-chain fatty acyl-CoAs are oxidized
by BCOX, DBP, and SCPx, whereas oxidation of VLCFA-CoAs involves SCOX, DBP, and both 3-ketoacyl-CoA thiolase and SCPx. “VLCFA-
CoA n-2” represents VLCFA-CoA shortened by two carbon atoms after one b-oxidation cycle.
idation defect present with neurological symptoms. In
most of the disorders, the neurological symptoms are
present from birth or childhood, but, in the majority of
patients with Refsum disease and AMACR deﬁciency,
these symptoms develop only after adolescence.
The patient we describe here, a 45-year-oldwhiteman,
was admitted to the hospital with a 28-year history of
dystonic head tremor and spasmodic torticollis. The pa-
tient reported that he had noticed a stutter for the ﬁrst
time when he was a 7-year-old boy. At age 17 years, he
observed a spasmodic torticollis to the left side, with a
dystonic head tremor in stressful situations. At age 29
years, he consulted a urologist for a fertility checkup,
and hypergonadotrophic hypogonadism and azoosper-
mia were diagnosed. The 44-year-old brother of the pa-
tient was fertile and did not have any neurological symp-
toms, whereas the 41-year-old brother was reported to
have similar neurological complaints as the patient. Ac-
cording to his mother, he is infertile and stutters; how-
ever, he declined to undergo neurological examination
or further diagnostic tests.
During the past several years, the dystonic symptoms
in the patient had worsened, and, when he was age 44
years, additional clinical and laboratory investigations
were performed. Cranial magnetic resonance imaging
(MRI) showed bilateral hyperintense signals in the thal-
amus, butterﬂy-like lesions in the pons, and lesions in
the occipital region, without gadolinium enhancement
(ﬁg. 2). Neurological examination revealed hyposmia,
pathological saccadic eye movements, and a slight hy-
poacusis, but it was otherwise a normal cranial nerve
examination. There were brisk deep-tendon reﬂexes of
the upper extremities but diminished reﬂexes of the
lower extremities, plantar sole responses, no pareses,
normal superﬁcial sensation (pin-prick, light touch, and
temperature), and a reduced vibration sense of 4/8 at
the lateral malleoli. There were signs of slight cerebellar
ataxia with a left-sided intention tremor, balance and
gait impairment, and a slight left-sided rebound phe-
nomenon. Ophthalmologic investigation revealed no
abnormalities.
A complete blood count, coagulation analysis, and
serum electrolytes and liver enzyme levels were normal.
Serum cholesterol was slightly elevated at 5.7 mmol/liter.
Copper and ceruloplasmin levels in serum and urine
were within the normal range. A lumbar puncture
yielded clear, colorless cerebrospinal ﬂuid (CSF) at nor-
mal pressure. The CSF contained 1 cell/ml, and the pro-
tein, lactate, and glucose concentrations were normal.
Because of the absence of pleiocytosis and the negative
results for oligoclonal bands, borrelia serology, and vi-
rological examination of CSF, an inﬂammatory central
nervous process was considered to be very unlikely.
Nerve conduction studies of the lower extremities
showed a predominantly motor and slight sensory neu-
ropathy, with conduction blocks in the tibial nerves, re-
duced motor action potentials in the left peroneal nerve,
and a reduced amplitude of the left sural nerve (table
1). Nerve conduction velocities of the right median nerve
displayed a reduced conduction velocity, normal F-wave
latencies, and normal motor action potentials. The mo-
tor-evoked potentials of the abductor digiti minimi mus-
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Figure 2 A, Axial T2-weighted MRI showing bilateral pons le-
sions. B, Axial T2-weighted MRI showing bilateral intense signals in
the thalamus. C, Coronal T1-weighted MRI showing bilateral involve-
ment of the pons and thalamus.
cle were prolonged and revealed double-sided lesions of
the pyramidal tract to the upper extremity. After cortical
stimulation, motor-evoked potentials of the tibial ante-
rior muscle were abolished, also suggesting bilateral py-
ramidal lesions to the legs. The sensory-evoked poten-
tials showed bilateral lesions of the posterior funiculus
of the spinal cord. The bilateral latencies of peak V of
the acoustic-evoked potentials and the interpeak latency
between peaks I and V and between peaks III and V
were prolonged, corresponding to a bilateral pontine
lesion (table 2). The blink reﬂex, with a reproducible
prolonged R2c latency after left stimulation, was com-
patible with a medullary lesion. Nystagmography showed
a spontaneous nystagmus to the left side, which could
be suppressed by ﬁxation; square wave jerks and slowed
saccades could be detected, indicating vestibulo-cere-
bellar lesions. Extracranial and transcranial Doppler
sonography showed normal results.
Because of a clinical suspicion of AMACR deﬁciency,
the plasma levels of the branched-chain fatty acids pris-
tanic acid and phytanic acid were measured. The level
of pristanic acid was markedly increased (39.8 mmol/
liter; control range 0–3.1 mmol/liter), and the level of
phytanic acid was slightly increased (10.1 mmol/liter;
control range 0–9 mmol/liter), whereas the level of the
straight-chain fatty acid C26:0 was just above the high-
est value of the normal range (table 3). Traces of the
bile acid intermediates DHCA and THCA were detect-
able in both plasma and urine. Subsequent investigations
in cultured skin ﬁbroblasts of the patient revealed a
strongly reduced b-oxidation activity with pristanic acid
as substrate (131 pmol/h/mg; control range 691–2,178
pmol/h/mg), normal C26:0 b-oxidation activity (1,048
pmol/h/mg; control range 1,025–2,994 pmol/h/mg), and
normal C26:0 level (0.31 mmol/g; control range 0.18–
0.38 mmol/g). The biochemical abnormalities were in-
dicative of AMACR deﬁciency, but, surprisingly, direct
measurement of AMACR activity in ﬁbroblasts showed
no abnormalities. Because of the reduced pristanic acid
b-oxidation activity, we measured the activity of all the
other enzymes involved in the peroxisomal breakdown
of branched-chain fatty acids. BCOX activity was nor-
mal, and DBP activity was even increased, but the ac-
tivity of SCPx, measured as described elsewhere,4 was
completely deﬁcient in ﬁbroblasts of the patient.
SCPx is a 58-kDa protein that consists of an amino-
terminal thiolase domain and a carboxy-terminal sterol
carrier protein 2 (SCP2) domain.5,6 After import into
peroxisomes, the domains are cleaved, giving rise to a
46-kDa thiolase and a 13-kDa SCP2.4,7 Immunoblot
analysis with an antibody against SCPx revealed the ab-
sence of both the full-length 58-kDa SCPx and the 46-
kDa thiolase domain of SCPx in ﬁbroblasts of the patient
(ﬁg. 3A). Because SCP2 also has its own promoter,5
immunoblot analysis with an antibody against SCP2
www.ajhg.org The American Journal of Human Genetics Volume 78 June 2006 1049
Table 1
Electrophysiological Findings in the SCPx-Deﬁcient Patient
A. Nerve Conduction Studies
PATIENT NORMAL RANGE
Amplitude
NCV
(m/s)
F-Wave
(ms) Amplitude
NCV
(m/s)
F-Wave
(ms)
Tibial nerve right 9.6/3.9a mV 44 56.5 12.6 mV 140 !51
Tibial nerve left 6.0/2.4amV 45 60.7 12.6 mV 140 !51
Peroneal nerve right 2.9/2.9amV 46 ND 12.7 mV 140
Peroneal nerve left 2.2/1.3amV 44 ND 12.7 mV 140
Median nerve right 7 mV 43 25 15 mV 150 !26
Sural nerve right 4 mV 42 NA 14 mV 141 NA
Sural nerve left 2.4 mV 44 NA 14 mV 141 NA
B. Sensory-Evoked Potentials
PATIENT NORMAL RANGE
P40
(ms)
ERB
(ms)
N20
(ms)
P40
(ms)
ERB
(ms)
N20
(ms)
Tibial nerve right NPR NA NA !45.7 NA NA
Tibial nerve left NPR NA NA !45.7 NA NA
Median nerve right NA 11 24.6 NA !12.1 !22
Median nerve left NA 11 24 NA !12.1 !22
C. Motor-Evoked Potentials
PATIENT NORMAL RANGE
Cortical
(ms)
IF
(ms)
F-Wave
(ms)
Cortical
(ms)
IF
(ms)
F-Wave
(ms)
TA muscle right NPR 19 60 !33.6 !17.5 !51
TA muscle left NPR 18.5 62 !33.6 !17.5 !51
ADM muscle right 23.1 15.3 27.2 !22.2 !15.4 !29
ADM muscle left 23.4 14.4 28 !22.2 !15.4 !29
D. Blink Reﬂex
PATIENT NORMAL RANGE
R1 R2 R2c R1 R2 R2c
Right 11.5 35.6 37.1 !12.2 !39.1 !40.1
Left 11.0 38.1 42.8 !12.2 !39.1 !40.1
NOTE.—ADM p abductor digiti minimi; IF p intervertebral foramen; NA p not ap-
plicable; NCV p nerve conduction velocities; ND p not done; NPR p no potential
recordable; TA p tibial anterior.
a Shown as distal stimulation/proximal stimulation.
Table 2
Acoustic-Evoked Potentials in the SCPx-Deﬁcient Patient
ACOUSTIC-EVOKED
POTENTIALS
LATENCY
(ms)
INTERPEAK LATENCY
(ms)
I III V I-III III-V I-V
Right 1.45 4.05 6.70 2.61 2.64 5.25
Left 1.46 4.12 6.65 2.66 2.52 5.19
Normal range !1.86 !4.16 !6.23 !2.72 !2.31 !4.67
showed the normal presence of the 13-kDa SCP2. The
classic peroxisomal 3-ketoacyl-CoA thiolase was also
normally present in ﬁbroblasts of the patient, as shown
by immunoblot analysis. To conﬁrm the SCPx deﬁciency
at the molecular level, we ampliﬁed the SCPx cDNA in
three overlapping fragments, followed by sequencing,
and found a homozygous 1-nt insertion (of an adenine)
at position 545 (545_546insA) (ﬁg. 3B) leading to a
frameshift and premature stop codon (I184fsX7). Ho-
mozygosity was conﬁrmed at the genomic level, and the
patient’s mother was heterozygous at the genomic level.
No biochemical abnormalities were found in plasma or
urine from the patient’s mother.
Because of the elevated pristanic acid levels, the pa-
tient began a phytanic acid–restricted diet. After 9 mo
of the diet, the phytanic acid levels in plasmawerewithin
the normal range and the pristanic acid levels had de-
creased to 6.2 mmol/liter. Another analysis, performed
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Table 3
Biochemical Data on Plasma and Fibroblasts from the Patient
and Control Subjects
SAMPLE AND
BIOCHEMICAL MEASURE PATIENT
CONTROL SUBJECTS
Mean SD Range
Plasma (mmol/liter):
Phytanic acid 10.1 2.8 2.1 0–9
Pristanic acid 39.8 .3 .4 0–3.1
DHCA .1 .003 .014 0–.13
THCA .1 .007 .019 0–.09
C26:0 1.34 .77 .19 .46–1.31
Fibroblasts:
C26:0a .31 .29 .06 .18–.38
C26:0 b-oxidationb 1,048 1,552 399 1,025–2,994
Pristanic acid b-oxidationb 131 1,450 393 691–2,178
Phytanic acid a-oxidationb 46 62 23 32–173
AMACR activityc 167 99 28 45–149
SCOX activityc 293 90 28 49–151
BCOX activityc 211 178 79 87–340
DBP-hydratase activityc 433 278 88 121–600
DBP-dehydrogenase
activityc 217 93 53 25–261
SCPx activityc NDd 86 28 49–139
a mmol/g.
b pmol/h/mg.
c pmol/min/mg.
d Not detectable.
Figure 3 A–C, Immunoblot analysis of ﬁbroblasts from two
control subjects, the SCPx-deﬁcient patient, two patients with Zell-
weger syndrome, and one patient with RCDP type 1. A, Antibody was
used against SCPx. The arrowheads indicate the 58-kDa full-length
protein and the 46-kDa thiolase domain of SCPx. B, Antibody was
used against SCP2 (13 kDa). C, Antibody was used against peroxi-
somal 3-ketoacyl-CoA thiolase. The arrowheads indicate the 44-kDa
precursor form and the 41-kDa mature form of 3-ketoacyl-CoA thio-
lase. D, Automated sequence analysis revealed a homozygous insertion
of an adenine (545_546insA) at both the cDNA and the genomic level,
leading to a frameshift and premature stop codon (I184fsX7).
after 14 mo of the diet, showed that the pristanic acid
levels had stabilized at a marginally elevated level (8.1
mmol/liter). The levels of C26:0 were completely normal
on both occasions (0.54 and 0.68 mmol/liter, respec-
tively). Since the beginning of the diet, no progression
of symptoms has been observed. A follow-up cranial
MRI showed no increase of the leukoencephalopathy.
Mice with a targeted disruption of the gene encoding
SCPx develop ataxia, reduced muscle tone, and periph-
eral neuropathy (uncoordinated movements, unsteady
gait, and trembling) when fed a phytol-enriched diet8
and thus closely resemble their human counterpart.
The present patient also shows striking similarities to
AMACR-deﬁcient patients, both at the clinical and at
the biochemical level. Themost prominent clinical symp-
tom of AMACR deﬁciency is adult-onset sensory motor
neuropathy,9–11 which was also present in our patient.
Similar to a recently described AMACR-deﬁcient pa-
tient, our patient showed high signals in the thalamus
and pons on MRI. These gray and white matter abnor-
malities are present not only in SCPx and AMACR de-
ﬁciencies but also in DBP deﬁciency.12 Remarkably, the
SCPx-deﬁcient patient does not have retinitis pigmen-
tosa, which is frequently observed in AMACR deﬁciency
and Refsum disease.9–11,13
Just like AMACR-deﬁcient patients, our patient ac-
cumulated pristanic acid. However, only trace amounts
of the bile acid intermediates DHCA and THCA were
detectable in plasma and urine. Bile and serum of SCPx
knockout mice contain increased levels of 3a,7a,12a-
trihydroxy-27-nor-5b-cholestane-24-one, which is
an alternative metabolite of the substrate of SCPx,
3a,7a,12a-trihydroxy-24-keto-cholestanoyl-CoA, and
is formed by decarboxylation.14 Interestingly, tandem
mass spectrometric analysis of urine from our patient
consistently showed large peaks, with m/z 611 and 627,
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Figure 4 Negative-ion electrospray tandem mass spectrometric analysis of urine bile acids and bile alcohols from the SCPx-deﬁcient
patient (A), a patient with CTX (B), and a control subject (C). Abnormal glucuronic acid conjugates of bile alcohols were detected in urine
from the SCPx-deﬁcient patient and the patient with CTX. We postulated the identity of the metabolites as follows: m/z 597, 27-nor-5b-
cholestanetetrol glucuronide; m/z 611, pentahydroxy-27-nor-5b-cholestane-24-one or 5b-cholestanetetrol glucuronides; m/z 613, 27-nor-5b-
cholestanepentol glucuronide; m/z 627, hexahydroxy-27-nor-5b-cholestane-24-one or 5b-cholestanepentol glucuronides; m/z 629, 27-nor-5b-
cholestanehexol glucuronide; and m/z 643, heptahydroxy-27-nor-5b-cholestane-24-one or 5b-cholestanehexol glucuronides.
which most likely correspond to pentahydroxy-27-nor-
5b-cholestane-24-one and hexahydroxy-27-nor-5b-
cholestane-24-one glucuronides, respectively (ﬁg. 4).
In addition, compounds with m/z 613 and 629 were
abundantly present, which most likely correspond to 27-
nor-5b-cholestanepentol and 27-nor-5b-cholestanehexol
glucuronides, respectively (ﬁg. 4). This may be consid-
ered indirect evidence of the inability to metabolize
3a,7a,12a-trihydroxy-24-keto-cholestanoyl-CoA and is
in full agreement with the ﬁndings in SCPx knockout
mice.14 Furthermore, the presence of large amounts of
bile alcohols in the patient’s urine suggests that the block
in bile acid biosynthesis at the level of SCPx may initiate
an alternative pathway for bile acid biosynthesis not
requiring a peroxisomal b-oxidation step—that is, the
microsomal 25-hydroxylase pathway.15 Metabolites of
this pathway, bile alcohols, are also found in patients
with cerebrotendinous xanthomatosis (CTX [MIM
213700])16 (ﬁg. 4), who have a deﬁciency of the mito-
chondrial 27-hydroxylase, which is a step upstream of
SCPx in bile acid biosynthesis. In plasma of the SCPx-
deﬁcient patient, 3a,7a,12a-trihydroxy-27-nor-5b-cho-
lestane-24-one could not be detected,most likely because
this compound is not ionized efﬁciently and therefore
cannot be detected using our tandemmass spectrometric
method.
In vitro studies have shown that both SCPx and the
classic 3-ketoacyl-CoA thiolase can handle VLCFAs as
substrates.1 Patients with rhizomelic chondrodysplasia
punctata (RCDP) type 1 (MIM 215100) lack 3-ketoacyl-
CoA thiolase in their peroxisomes because of a defect
in PEX7, the gene encoding the peroxisome-targeting
signal 2 receptor.17,18 Although 3-ketoacyl-CoA thiolase
is mistargeted in RCDP type 1, no abnormality in
VLCFA b-oxidation has been observed in patients,19,20
which suggests that SCPx can take over its function for
the straight-chain fatty acyl-CoAs. The fact that our
SCPx-deﬁcient patient had normal levels of VLCFAs sug-
gests that the classic 3-ketoacyl-CoA thiolase also can
maintain normal VLCFA b-oxidation activity in the ab-
sence of SCPx.
In conclusion, we have identiﬁed the ﬁrst known pa-
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tient with SCPx deﬁciency. This patient presented with
dystonia, a predominant motor neuropathy, advanced
leukoencephalopathy with cerebellar signs, and involve-
ment of the pyramidal tract and the posterior columns.
Our ﬁndings imply that the group of single peroxisomal
b-oxidation enzyme deﬁciencies extends to AMACR,
SCOX, DBP, and SCPx deﬁciencies. The elucidation of
the true defect in this case has increased our knowledge
of the peroxisomal b-oxidation system and its substrates
and of the clinical consequences of metabolic derange-
ments associated with defects in the peroxisomal b-ox-
idation system.
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